Paclitaxel Articles
Spectrum gets world rights to ortataxel
20 August 2007
TopoTarget initiates Ph II bladder cancer belinostat trial
13 August 2007
Abraxis out-licenses Abraxane for India
13 August 2007
CHMP recommends approval of Avastin for NSCLC
30 July 2007
Taihua's pretax 2006 profits leap 74%
16 July 2007
Satraplatin cuts progression in prostate cancer
11 June 2007
GSK's Tykerb shows potential in breast cancer
11 June 2007
Synta's STA-4783 boosts melanoma patient survival
11 June 2007
Lilly reports benefits of Alimta in NSCLC
11 June 2007
Indena's new synthetic paclitaxel plant opens
4 June 2007
Bioxel expands EU cancer durg API list
21 May 2007
Roche's Avastin launched in the UK
21 May 2007
Antisoma reports promising preclinical data
23 April 2007
Preclinical data suggests combo role for Proxinium
23 April 2007
Stock Commentary - Europe - week to April 16, 2007
23 April 2007
Japan stock market week to April 16, 2007
23 April 2007
Fast-track for Cell Thera's Xyotax
23 April 2007
EC expands indication for Roche's Avastin
9 April 2007
Protherics begins recruitment in Oncogel trial
2 April 2007
Combined Reolysin effective in animal cancer models
26 March 2007
Antisoma sees strong Ph II AS1404 data in NSCLC
19 March 2007
S-P's Caelyx impresses in Ph II cancer trial
26 February 2007
Boston's Taxus stent gets CE mark for new sizes
12 February 2007
China's Taihua to sell paclitaxel in Korea
12 February 2007
Update: Rumors say Sanofi to merge with B-MS
5 February 2007
B-MS swings to loss in 4th qtr due to Plavix
5 February 2007
Boston Sci's Taxus favorable TLR rate vs J&J's Cypher
22 January 2007
Roche's Avastin is first drug to extend survival in patients with advanced NSCLC beyond one year
22 December 2006
Protherics upbeat despite higher losses
18 December 2006
November a lackluster month for biotechnology stocks, says Burrill
18 December 2006
Nexavar fails in Ph III melanoma study
11 December 2006
Herceptin gets FDA ok for HER2 node
27 November 2006
J&J to boost Cordis unit with Conor Med
27 November 2006
PXD101 shows efficacy in Ph Ib cancer study
20 November 2006
Genta's Genasense shows preclinical efficacy
20 November 2006
Cell Thera temporarily halts PIONEER study enrollment
13 November 2006
Abbott's Xience stent fares well in diabetics
6 November 2006
Genentech's blockbuster Avastin gains new cancer indication; $2B sales predicted in 2007
23 October 2006
Cell Therapeutics licenses global Xyotax rights to Novartis
2 October 2006
Rumors that Mayne will float on the LSE
11 September 2006
Cell Thera's Xyotax yields 91% tumor response in Ph I trial
28 August 2006
Paris listing for Chinese pharma
28 August 2006
US FDA fast-tracks Novelos' NOV-002
14 August 2006
Immutep begins Ph I ImmuFact cancer study
14 August 2006
Tavocept falls short in Ph III neuropathy trials
7 August 2006
New Indian drug price cuts of 10%-70%
26 June 2006
Genentech submits Avastin sBLA to US FDA
5 June 2006
Oxigene's CA4P gets FDA OD
22 May 2006
Boston's TAXUS Liberte gets expanded EU label
22 May 2006
Enrollment complete in two Ph III Nexavar trials
15 May 2006
B-MS's earnings hit $714M in 1st-qtr
8 May 2006
Abraxis to buy Puerto Rico unit from Pfizer
1 May 2006
APP and American Biosci complete merger to form Abraxis
24 April 2006
Genentech submits Avastin NSCLC sBLA
17 April 2006
Strong animal data for SDP-103
3 April 2006
Enrollment complete in OXiGENE's CA4P trial
3 April 2006
Conor licenses pimecrolimus from Novartis
20 March 2006
Study reveals Taxus stent's superiority to Cypher
20 March 2006
Strong animal data for Ark's Scavidin
27 February 2006
Bayer/Onyx launch Ph III Nexavar trial
27 February 2006
Cinnamon can lower blood sugar levels
20 February 2006
Boston's Taxus Liberte reimbursed by French government
20 February 2006
Cell Thera's Xyotax fast tracked by US FDA
20 February 2006
4th-qtr 2005 sales drop 1% for B-MS, as patents lost
30 January 2006
Boston Scientific reports 4th-qtr sales downturn
16 January 2006
Spectrum initiates Ph II satraplatin trials
19 December 2005
GPC Biotech's satraplatin enters Ph II as Taxol combo
19 December 2005
Rationale for Cell Thera's Xytoax enhanced survival in NSCLC
19 December 2005
GPC begins Ph II satraplatin trial
19 December 2005
Cell Thera to start Xyotax NSCLC trial in women
12 December 2005
American Pharma to buy shareholder
5 December 2005
Dosing starts in TopoTarget/CuraGens' Ph Ib trial of PXD101
19 September 2005
Boston Scientific gains European approval for new stent system
19 September 2005
EPO Angiotech patent decision unchallenged
15 August 2005
UK fast-tracks Velcade, Herceptin through NICE
25 July 2005
Cell Thera's Xyotax sees strong Ph III results
18 July 2005
Promising interim data for Telik's Telcyta
11 July 2005
Operational changes at InB:Paxis
11 July 2005
FDA OK's extended shelflife for TAXUS
6 June 2005
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
